Effects of atorvastatin on development of peritoneal fibrosis in rats on peritoneal dialysis

Renal Failure

Volumn 32, Issue 9, 2010, Pages 1095-1102

  Yeniçerioglu, Yavuz ^a   Üzelce, Özlem ^a   Akar, Harun ^a   Kolatan, Efsun ^b   Yilmaz, Osman ^b   Yenisey, Çigdem ^a   Sarioglu, Sulen ^b   Meteoglu, Ibrahim ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

atorvastatin; peritoneal dialysis; peritoneal fibrosis; statins; TGF

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; CATALASE; DIANEAL; GLUCOSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIALYSATE LEVEL; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FIBROSIS; FUNCTION TEST; HISTOPATHOLOGY; INFLAMMATION; NONHUMAN; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEUM; PERITONEUM EQUILIBRATION TEST; PERITONEUM FIBROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; THICKNESS; TREATMENT DURATION; VASCULARIZATION; WISTAR ALBINO GLAXO RAT;

ANIMALS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PYRROLES; RATS; RATS, WISTAR;

EID: 77957259914     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.508859     Document Type: Article

References (63)

1. Jimenez-Heffernan JA, Aguilera A, Aroeira LS, et al. Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. Virchows Arch. 2004;444:247-256. (Pubitemid 38446437)
2. Nishino T, Miyazaki M, Abe K, et al. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int. 2003;64(3):887-896. (Pubitemid 37013824)
3. Günal AI, Duman S, Sen S, et al. By reducing TGFβ1, octreotide lessens the peritoneal derangements induced by a high glucose solution. J Nephrol. 2001;14:184-189. (Pubitemid 32586323)
4. Selgas R, Fernandez-Reyes MJ, Bosque E, et al. Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis. 1994;23(1):64-73. (Pubitemid 24021750)
5. Di Paolo N, Garosi G. Peritoneal sclerosis. J Nephrol. 1999;12(6):347-361. (Pubitemid 30014647)
6. Plum J, Hermann S, Fusshöller A, et al. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int Suppl. 2001;78: S42-S47. (Pubitemid 32144068)
7. Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron. 1996;72(2): 171-176. (Pubitemid 26035372)
8. Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1991;18(1):97-102.
9. Duman S, Sen S, Duman C, Oreopoulos DG. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs. 2005;28(2):156-163. (Pubitemid 40485215)
10. Duman S, Wieczorowska-Tobis K, Styszynski A, Kwiatkowska B, Breborowicz A, Oreopoulos DG. Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum. Adv Perit Dial. 2004;20:31-36.
11. Gunal AI, Celiker H, Akpolat N, Ustundag B, Duman S, Akcicek F. By reducing production of vascular endothelial growth factor octreotide improves the peritoneal vascular alterations induced by hypertonic peritoneal dialysis solution. Perit Dial Int. 2002;22(3):301-306.
12. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl. 1999;71:S2-S5. (Pubitemid 29304801)
13. Schonbeck U, Libby P. CD40 signalling and plaque instability. Circ Res. 2001;89:1092-1103.
14. Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res. 1999;41:402-417. (Pubitemid 29087337)
15. Koh KK. Effects of statins vascular wall: Vasomotor function, inflammation and plaque stability. Cardiovasc Res. 2000;47:648-657.
16. Yoshino G, Hirano T, Kazumi T. Fluvastatin increases LDL particle size and reduces oxidative stress in patients with hyperlipidemia. J Atheroscler Thromb. 2003;10(6):343-347.
17. Marumo H, Satoh K, Yamamoto A, Kaneta S, Ichihara K. Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats. Yakugaku Zasshi. 2001;121(10):761-764. (Pubitemid 33021587)
18. Ersoy R, Celik A, Yilmaz O, et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int. 2007;27(4):424-431. (Pubitemid 47202195)
19. Mateijsen MA, van der Wal AC, Hendriks PM, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int. 1999;19:517-525.
20. Bunke CM, Brier ME, Golper TA. Outcomes of single organism peritonitis in peritoneal dialysis: Gram negatives versus gram positives in the Network 9 Peritonitis Study. Kidney Int. 1997;52:524-529.
21. Lowry O, Rosenbraugh N, Farr L, Rondall R. (1951) Protein measurement with the folinphenol reagent. J Biol Chem. 1951;193(1):265-275.
22. Tietze, F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Applications to mammalian blood and other tissues. Anal Biochem. 1969;27(3):502-522.
23. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351-358. (Pubitemid 9194347)
24. Navarro-Gonzalves JA, Garcia-Benayas C, Arenas J. Semiautomated measurement of nitrate in biological fluids. Clin Chem. 1998;44:679-681. (Pubitemid 28141376)
25. Aebi H. Catalase. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press; 1974:673-677.
26. Racker E. Glutathione reductase (liver and yeast). In: Colowick SP, Kaplan NO, eds. Methods in Enzymology. Vol.2. New York: Academic Press; 1955:722-729.
27. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant. 1996;11(3):498-506. (Pubitemid 26092790)
28. Kaneko K, Hamada C, Tomino Y. Peritoneal fibrosis intervention. Perit Dial Int. 2007;27(Suppl. 2):S82-S86. (Pubitemid 350047682)
29. Goffin E. Peritoneal membrane structural and functional changes during peritoneal dialysis. Semin Dial. 2008;21(3): 258-265.
30. Devuyst O, Topley N, Williams J. Morphological functional changes in the dialysed peritoneal cavity: Impact of more biocompatible solutions. Nephrol Dial Transplant. 2002;17(Suppl. 3):12-15. (Pubitemid 34450111)
31. Saxena R. Pathogenesis and treatment of peritoneal membrane failure. Pediatr Nephrol. 2008;23(5):695-703. (Pubitemid 351486181)
32. Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13(2):470-479. (Pubitemid 34106290)
33. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int. 2000;20(Suppl. 4):22-42.
34. Gotloib L, Wajsbrot V, Shostak A. A short review of experimental peritoneal sclerosis: From mice to men. Int J Artif Organs. 2005;28(2):97-104. (Pubitemid 40485207)
35. Margetts PJ, Kolb M, Yu L, Hoff CM, Gauldie J. A chronic inflammatory infusion model of peritoneal dialysis in rats. Perit Dial Int. 2001;21(Suppl. 3):S368-S372. (Pubitemid 34406838)
36. Zweers MM, De Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med. 1999;134(2):124-132. (Pubitemid 29375441)
37. Coles GA, Williams JD, Topley N. Peritoneal inflammation and long-term changes in peritoneal structure and function. In: Gokal R, Khanna R, Krediet RT, Nolph KD, eds. Textbook of Peritoneal Dialysis. 2nd ed., Oxford: Kluwer Academic Publishers; 2000:566-583.
38. Di Paolo N, Gaggiotti E. Theoretical morphological approach to simple peritoneal sclerosis. Int J Artif Organs. 2005;28(2): 85-89. (Pubitemid 40485205)
39. Duman S, Ozbek SS, Gunay ES, et al. What does peritoneal thickness in peritoneal dialysis patients tell us? Adv Perit Dial. 2007;23:28-33.
40. Honda K, Nitta K, Horita S, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant. 1999;14(6):1541-1549. (Pubitemid 29241752)
41. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor b in human disease. N Engl J Med. 2000;342: 1350-1359.
42. Margetts PJ, Kolb M, Yu L, et al. Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol. 2002;160(6):2285-2294. (Pubitemid 34663419)
43. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int. 2003;23(6): 530-541. (Pubitemid 37527296)
44. Garosi G, Di Paolo N. Morphological aspects of peritoneal sclerosis. J Nephrol. 2001;14(Suppl. 4):S30-S38. (Pubitemid 33743238)
45. Imai H, Nakamoto H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of adhesion molecules in the progression of peritoneal sclerosis. Adv Perit Dial. 2003;19:180-185.
46. Massy ZA, Guijarro C. Statins: Effects beyond cholesterol lowering. Nephrol Dial Transplant. 2001;16(9):1738-1741. (Pubitemid 32821398)
47. Oh KH, Margetts PJ. Cytokines and growth factors involved in peritoneal fibrosis of peritoneal dialysis patients. Int J Artif Organs. 2005;28(2):129-134. (Pubitemid 40485211)
48. Fang CC, Yen CJ, Chen YM, et al. Pentoxifylline inhibits human peritoneal mesothelial cell growth and collagen synthesis: Effects on TGF-b. Kidney Int. 2000;57(6):2626-2633.
49. Duman S, Sen S, Sozmen EY, Oreopoulos DG. Atorvastatin improves peritoneal sclerosis induced by hypertonic PD solution in rats. Int J Artif Organs. 2005;28(2):170-176. (Pubitemid 40485217)
50. Zhang W, Liu M, Wu Y, et al. Protective effects of atorvastatin on chronic allograft nephropathy in rats. J Surg Res. 2007;143(2):428-436. (Pubitemid 350101566)
51. Asberg A, Hartmann A, Fjeldså E, Holdaas H. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant. 2001;16(9):1920-1924. (Pubitemid 32821428)
52. Kumar S, Thuraisingham RC, Raftery MJ, Fan SL, Yaqoob MM. Statins have anti-inflammatory effects in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol. 2003;14:737.
53. Li C, Yang CW, Park JH, et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol. 2004;286(1):F46-F57. (Pubitemid 38045041)
54. Li C, Sun BK, Lim SW, et al. Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation. 2005;79(11):1522-1529. (Pubitemid 40847583)
55. Sabbatini M, Pisani A, Uccello F, et al. Atorvastatin improves the course of ischemic acute renal failure in aging rats. J Am Soc Nephrol. 2004;15(4):901-909. (Pubitemid 38375309)
56. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19(1):128-139 (Review).
57. Paraskevas KI. Statin therapy in peritoneal dialysis patients: Effects beyond lipid lowering. Int Urol Nephrol. 2008;40(1): 165-170.
58. Goppelt-Struebe M, Hahn A, Iwanciw D, Rehm M, Banas B. Regulation of connective tissue growth factor (ccn2; ctgf) gene expression in human mesangial cells: Modulation by HMG CoA reductase inhibitors (statins). Mol Pathol. 2001;54(3): 176-179. (Pubitemid 32539610)
59. Guijarro C, Egido J. Transcription factor B (NF B) and renal disease. Kidney Int. 2001;59:415-424.
60. Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O'Donnell MP. Low-density lipoprotein-induced expression of interleukin-6 a marker of human mesangial cell inflammation: Effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267:536-540. (Pubitemid 30076833)
61. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol. 2002;2(1):46-53. (Pubitemid 37328775)
62. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007;20(5):440-451.
63. Antoniadi G, Eleftheriadis T, Liakopoulos V, et al. Effect of one-year oral alpha-tocopherol administration on the antioxidant defense system in hemodialysis patients. Ther Apher Dial. 2008;12(3):237-242. (Pubitemid 351743606)